CC
DYN icon

Corton Capital’s Dyne Therapeutics DYN Stock Holding History

Corton Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,926
Closed -$179K – 600
2023
Q3 		$179K Buy
19,926
+6,793
+52% +$73.2K 0.09% 329
2023
Q2 		$148K Buy
+13,133
New +$155K 0.07% 366

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Corton Capital's DYN Position: Q4 2023 in Review

Corton Capital sold out of Dyne Therapeutics (DYN) in Q4 2023, closing a stake of 19,926 shares — an estimated $179K sold.

Corton Capital first reported a position in DYN in Q2 2023 and held it in 2 quarters. The position peaked at $179K in Q3 2023. 124 funds tracked by Wall St. Rank hold DYN as of Q4 2023.

  • Corton Capital reported no remaining Dyne Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Corton Capital sold 19,926 Dyne Therapeutics shares in Q4 2023, an estimated $179K.
  • Corton Capital first reported a position in Dyne Therapeutics in Q2 2023 and held it in 2 quarters.
  • Corton Capital's Dyne Therapeutics position peaked at $179K in Q3 2023.
  • 124 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2023.

Based on Corton Capital's 13F filing for Q4 2023, filed 14 Feb 2024.